Analyst Vamil Divan works at MIZUHO and is focused on the Healthcare sector with 512 price targets and ratings documented since 2013 spanning on 21 stocks. Analyst's average stock valuation to be materialised ratio is 67.3% with an average time for price targets to be met of 204.35 days.
Most recent stock forecast was given on STSA, Satsuma Pharmaceuticals, Inc at 15-Nov-2022.
Vamil Divan best performing recommendations are on KRTX (KARUNA THERAPEUTICS, INC).
The best stock recommendation documented was for KRTX (KARUNA THERAPEUTICS, INC) at 8/9/2022. The price target of $276 was fulfilled within 3 days with a profit of $47.55 (20.81%) receiving and performance score of 69.38.
Average potential price target upside